Geng Mingying, Song Yang, Xiao He, Wu Zhiyu, Deng Xiaojuan, Chen Chuan, Wang Ge
Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing 400042, P.R. China.
Department of Clinical Laboratory, Daping Hospital, Army Medical University, Chongqing 400042, P.R. China.
Oncol Lett. 2021 Jan;21(1):2. doi: 10.3892/ol.2020.12263. Epub 2020 Nov 3.
The diagnostic and prognostic evaluation of primary central nervous system lymphoma (PCNSL) is challenging due to the lack of sensitive biomarkers. The present study aimed to evaluate the value of interleukin (IL)-10 in this context. Between October 2016 and December 2018, 91 patients with suspected intracranial neoplasms were recruited, and the concentrations of IL-10 or IL-6 in both the cerebrospinal fluid (CSF) and blood were measured and analyzed by the Kruskal-Wallis test. The correlation between CSF IL-6 or IL-10 levels and tumor size was determined by Spearman's coefficient analysis. The receiver operating characteristic curve was used to evaluate the diagnostic value of CSF IL-6 and IL-10 levels. Median progression-free survival (PFS) and overall survival time were calculated using Kaplan-Meier survival analysis. Among the 91 patients, 3 were diagnosed with PCNSL on the basis of neuroimaging data and CSF IL-10 levels. A total of 35 cases were verified to show diffuse large B-cell lymphoma on histological assessment, 17 of which were diagnosed as PCNSL by MRI. The median PFS and OS were 8.00 months [95% confidence interval (CI), 3.94-12.06) and 17.5 months (95% CI, 11.55-23.45) respectively in the 12 PNCSL cases with regular follow up. The diagnostic efficiency of serum IL-6 levels was lower than that of serum IL-10 levels (P=0.030), which, in turn, was lower than that of CSF IL-10 levels (P<0.001). The decline and increase in CSF IL-10 levels was concurrent with improvement and deterioration in manifestation, respectively, which predated the MRI variation. High CSF IL-10 levels indicated low Karnofsky performance scale scores and shortened PFS times. CSF IL-10 levels higher than 1,000 pg/ml signified disease progression. CSF IL-10 levels could be a sensitive biomarker guiding the differential diagnosis, early recurrence detection, prognostic evaluation and therapeutic strategy establishment in cases of PCNSL.
由于缺乏敏感的生物标志物，原发性中枢神经系统淋巴瘤（PCNSL）的诊断和预后评估具有挑战性。本研究旨在评估白细胞介素（IL）-10在此方面的价值。2016年10月至2018年12月，招募了91例疑似颅内肿瘤患者，通过Kruskal-Wallis检验测量并分析脑脊液（CSF）和血液中IL-10或IL-6的浓度。通过Spearman系数分析确定CSF IL-6或IL-10水平与肿瘤大小之间的相关性。采用受试者工作特征曲线评估CSF IL-6和IL-10水平的诊断价值。使用Kaplan-Meier生存分析计算中位无进展生存期（PFS）和总生存时间。在91例患者中，3例根据神经影像学数据和CSF IL-10水平被诊断为PCNSL。组织学评估共证实35例为弥漫性大B细胞淋巴瘤，其中17例经MRI诊断为PCNSL。在12例接受定期随访的PNCSL病例中，中位PFS和OS分别为8.00个月[95%置信区间（CI），3.94-12.06）和17.5个月（95%CI，11.55-23.45）。血清IL-6水平的诊断效率低于血清IL-10水平（P=0.030），而血清IL-10水平又低于CSF IL-10水平（P<0.001）。CSF IL-10水平的下降和升高分别与临床表现的改善和恶化同时出现，且早于MRI变化。高CSF IL-10水平表明卡氏功能状态评分低且PFS时间缩短。CSF IL-10水平高于1000 pg/ml表示疾病进展。CSF IL-10水平可能是指导PCNSL病例鉴别诊断、早期复发检测、预后评估和治疗策略制定的敏感生物标志物。
